Vildagliptin with metformin once-daily regimen-insights from a single-center analysis.

Authors:
Dr Saurav Chatterjee, MD
Dr Saurav Chatterjee, MD
Mount Sinai St Luke's-Roosevelt Hospitals
Fellow
Cardiovascular Diseases
New York, New York | United States
Dr Sanjay Chatterjee, MD
Dr Sanjay Chatterjee, MD
Apollo Gleneagles Hospital
Consultant Diabetologist
Diabetology
Kolkata, West Bengal | India

Am J Ther 2015 May-Jun;22(3):195-8

1Consultant Physician, Diabetes Clinical Nutrition, Apollo Gleneagles Hospital, Kolkata, India; and 2Fellow, Preventive Cardiology, Brown University & VA Medical Center, Providence, RI.

Dipeptidyl peptidase-4 (DPP-4) inhibitors have been well established as an adjunctive treatment to metformin. Most guidelines recommend treatment with a DPP-4 inhibitor, vildagliptin, in addition to metformin in a twice-daily regimen. However, the twice-daily regimen has difficulty with medication adherence, increased cost of therapy, and possibility of more side effects. Our objective was to evaluate, by means of retrospective analysis, the efficacy of once-daily metformin and vildagliptin (a DPP-4 inhibitor) in reducing blood glucose for patients on combination therapy. We analyzed data from our database of outpatients attending the diabetic clinic at a tertiary care center in Kolkata, India. We had data on once-daily combination of metformin and vildagliptin for 154 patients between September 2008 and May 2012. We followed up these patients for a median of 17.6 months and evaluated posttherapy glucose levels and hemoglobin A1c. Continuous variables were compared with t tests. Once-daily metformin-vildagliptin combination was found to be associated with a mean reduction of 27.52 mg/dL of fasting plasma glucose, 71.70 mg/dL of postprandial plasma glucose, and 1.41% reduction of HbA1c (P < 0.05 for all). Metformin-vildagliptin combination in a once-daily regimen seems to be associated with significant reductions in plasma glucose and HbA1c and may be a viable and cost-effective alternative to a twice-daily regimen as starting therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MJT.0b013e3182811a8bDOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
February 2016
75 Reads
1.130 Impact Factor

Publication Analysis

Top Keywords

twice-daily regimen
12
plasma glucose
12
dpp-4 inhibitor
8
metformin-vildagliptin combination
8
metformin vildagliptin
8
glucose
5
once-daily
5
patients september
4
september 2008
4
154 patients
4
once-daily combination
4
combination metformin
4
vildagliptin 154
4
patients median
4
months evaluated
4
evaluated posttherapy
4
176 months
4
median 176
4
2012 patients
4
data once-daily
4

Similar Publications